AMENDMENT TO LICENSE AGREEMENT (UM97-14)
EXHIBIT 10.18
AMENDMENT TO LICENSE AGREEMENT (UM97-14)
Amendment to the License Agreement (the "Amendment") dated the 11th day of July, 2008 (the "Effective Date"), by and between the University of Miami and its School of Medicine ("LICENSOR"), and HEAT BIOLOGICS, INC., a Delaware corporation ("LICENSEE"), under the direction of Xx. Xxxxxxx Podack, to wit: LICENSE AGREEMENT relating to the technology and product identified as the Podack Cancer Vaccine (VM97-14) , and hereinafter referred to as "License Agreement".
WHEREAS, LICENSOR and LICENSEE entered into that certain Stockholders Agreement dated the 11th day of July, 2008, granting to the LICENSOR certain rights to participate in future stock offerings by the LICENSEE (hereinafter referred to as the "Stockholders Agreement"); and
WHEREAS, LICENSOR is the owner and holder of eight percent (8%) of all issued and outstanding common stock of LICENSEE in each class and series on a fullydiluted basis pursuant to the terms and conditions of the License Agreement; together with the University of Miami Investor Rights Agreement effective July I 1, 2008, and the Common Stock Subscription Agreement dated July 1, 2008; and
WHEREAS, LICENSEE has a past due and outstanding license issue fee obligation to LICENSOR, as set forth in section 8.1(a) of the License Agreement, as follows:
One hundred fifty thousand ($150,000.00) dollars obligation, past due and outstanding, to wit: Payable within thirty (30) days of the Effective Date, on or before August 11, 2008; and
WHEREAS, LICENSEE has past due and outstanding patent fees and costs obligations to LICENSOR in the amount of eleven thousand seventeen and 09/1 00 ($11, 017.09) dollars pursuant to section 5.1 of the License Agreement; and
WHEREAS, LICENSEE has a past due and outstanding license issue fee obligation together with past due and outstanding patent fees and costs obligations to LICENSOR pursuant to the License Agreement, in the total amount of one hundred sixty one thousand seventeen and 09/100 ($161,017.09) dollars; and
WHEREAS, LICENSEE has requested an extension of the payment dates for past due license issue fees together with past due patent fees and costs, and LICENSOR desires to extend the foregoing payment dates.
NOW THEREFORE, for the mutual promises and other good and valuable consideration contained herein, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:
LICENSOR agrees to extend the payment dates of the foregoing past due license issue fee together with past due patent fees and costs owed by LICENSEE pursuant to the License Agreement, under the following terms and conditions:
1.
LICENSOR shall extend the payment deadline of all past due license issue fees and past due patent fees and costs under the License Agreement, in the total amount of one hundred sixty one thousand seventeen and 09/100 ($161,017.09) dollars to August 11, 2009 (the "Extension Date")
2.
LICENSOR shall be issued two and one half percent (2.5%) fully-dilutable common shares of the total number of LICENSEE common shares issued and outstanding, which stock issuance shall be evidenced as follows:
Section 8.5 of the License Agreement is hereby amended and restated in its entirety to read as follows:
As partial consideration for the license granted pursuant to this Agreement, LICENSEE shall issue to LICENSOR a fully paid, nonassessable number of common shares equal to eight percent (8%) of the total number of LICENSEE issued and outstanding common shares in each class and series on a fully-diluted basis, at all times until and including the later of such time that LICENSEE has received more than two million dollars ($2,000,000) in cash proceeds after the Effective Date of this Agreement from equity investments by parties unaffiliated with LlCENSEE as of the Effective Date of this Agreement ("Qualified Investment"). For the avoidance of doubt, such anti-dilution protection for the foregoing shares shall continue to apply through the duration of and until immediately after, the Qualified Investment pursuant to this Agreement and any Amendments thereto, whichever is later. Furthermore, LICENSEE shall issue to LICENSOR fully-dilutable common shares equal to two and one half percent (2.5%) of the total number of LICENSEE common shares in each class and series issued and outstanding. LICENSEE shall affect the issuance of the foregoing fully-diluted shares by concurrent execution of an appropriate Stockholders Agreement, Investor Rights Agreements, and Common Stock Subscription Agreement, together with appropriate Amendments thereto evidencing the foregoing issuance of such fully-dilutable common shares to LICENSOR, the terms of which are incorporated by reference herein.
3.
LICENSEE shall pay LICENSOR, as additional consideration for the payment Extension Date granted by LICENSOR under this Amendment, the sum of twelve thousand five hundred ($12,500.00) dollars, to be due and payable on or before such Extension Date.
4.
LICENSOR hereby reserves the right, at its sale and absolute discretion, to seek any and all remedies available at law or in equity, for the nonpayment by the LICENSEE of any and all license issue fees together with patent fees and costs due and payable by the Extension Date.
5.
LICENSOR and LICENSEE mutually agree and confirm that the following sections of the License Agreement remain in full force and effect, and agree to be bound by the terms and conditions specified therein: section 6. entitled INDEMNIFICATION, section 21. entitled AMENDMENT, and section 25. entitled ENTIRE AGREEMENT. LICENSOR and LICENSEE further mutually agree and confirm that in all other respects the License Agreement shall remain in full force and effect in accordance with all other terms and conditions specified therein, and agree to be bound by the terms and conditions set forth therein.
This Amendment is entered into and made effective as of the last signature date set forth below.
IN WITNESS WHEREOF, the parties have executed this Amendment as of the date set forth below.
LICENSOR:
UNIVERSITY OF MIAMI
By: |
|
|
| Xxxx Xxxxxxx, M.D. |
|
| Director of UM Innovation Vice Xxxxxxx of Technology |
|
Date: _______ Advancement
LICENSEE:
By: |
|
|
| Xxxxxxx Xxxx |
|
| President |
|
